DE60023138D1 - Verwendung eines biologisch abbaubaren Polymers - Google Patents

Verwendung eines biologisch abbaubaren Polymers

Info

Publication number
DE60023138D1
DE60023138D1 DE60023138T DE60023138T DE60023138D1 DE 60023138 D1 DE60023138 D1 DE 60023138D1 DE 60023138 T DE60023138 T DE 60023138T DE 60023138 T DE60023138 T DE 60023138T DE 60023138 D1 DE60023138 D1 DE 60023138D1
Authority
DE
Germany
Prior art keywords
biodegradable polymer
solid tumor
phosphoester
mammal
inhibit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023138T
Other languages
English (en)
Other versions
DE60023138T2 (de
Inventor
Wenbin Dang
I Garver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Guilford Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc filed Critical Guilford Pharmaceuticals Inc
Publication of DE60023138D1 publication Critical patent/DE60023138D1/de
Application granted granted Critical
Publication of DE60023138T2 publication Critical patent/DE60023138T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DE60023138T 1999-03-26 2000-03-20 Verfahren und Zusammensetzung zur Behandlung von soliden Tumoren Expired - Lifetime DE60023138T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US276866 1999-03-26
US09/276,866 US6537585B1 (en) 1999-03-26 1999-03-26 Methods and compositions for treating solid tumors
PCT/US2000/007304 WO2000057852A2 (en) 1999-03-26 2000-03-20 Methods and compositions for treating solid tumors

Publications (2)

Publication Number Publication Date
DE60023138D1 true DE60023138D1 (de) 2006-02-23
DE60023138T2 DE60023138T2 (de) 2006-08-17

Family

ID=23058398

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023138T Expired - Lifetime DE60023138T2 (de) 1999-03-26 2000-03-20 Verfahren und Zusammensetzung zur Behandlung von soliden Tumoren

Country Status (17)

Country Link
US (2) US6537585B1 (de)
EP (1) EP1185249B1 (de)
JP (2) JP2002540137A (de)
KR (1) KR20010111578A (de)
CN (1) CN1367684A (de)
AT (1) ATE306251T1 (de)
AU (1) AU778279B2 (de)
BR (1) BR0009213A (de)
CA (1) CA2368621C (de)
CZ (1) CZ20013260A3 (de)
DE (1) DE60023138T2 (de)
HU (1) HUP0201436A3 (de)
IL (1) IL145492A0 (de)
NO (1) NO20014662L (de)
PL (1) PL351280A1 (de)
TR (1) TR200102801T2 (de)
WO (1) WO2000057852A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350464B1 (en) * 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US20020041897A1 (en) * 2000-07-07 2002-04-11 Wenbin Dang Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
WO2002005800A2 (en) * 2000-07-17 2002-01-24 Guilford Pharmaceuticals, Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
US20020198135A1 (en) * 2000-10-12 2002-12-26 Wenbin Dang Compositions for release of radiosensitizers, and methods of making and using the same
US20020141966A1 (en) * 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
US20020081339A1 (en) * 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
US7417110B2 (en) * 2001-05-14 2008-08-26 Jun Wang Biodegradable polyphosphoramidates for controlled release of bioactive substances
WO2002092667A1 (en) * 2001-05-14 2002-11-21 Johns Hopkins Singapore Pte Ltd. Biodegradable polyphosphates for controlled release of bioactive substances
US20030133903A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of prostate cancers and methods of making and using the same
US20030134892A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of head and neck cancers, and methods of making and using the same
US20050238616A1 (en) * 2002-01-09 2005-10-27 Guilford Pharmaceuticals, Inc. Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
WO2003080629A2 (en) * 2002-02-25 2003-10-02 Guilford Pharmaceuticals, Inc. Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
WO2005041936A2 (en) * 2003-10-21 2005-05-12 Psimedica Limited Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
US20060018948A1 (en) * 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
US20080124400A1 (en) * 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
UA90493C2 (ru) * 2004-12-06 2010-05-11 Сайклон Фармасютикалс, Инк Альфа-тимозиновые пептиды как адьюванты противораковых вакцин
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR101914254B1 (ko) 2005-02-18 2018-11-02 아브락시스 바이오사이언스, 엘엘씨 치료제의 조합 및 투여 방식, 및 조합 요법
EP1922094B1 (de) * 2005-08-12 2015-09-30 Jiang Liu Vorrichtungen für lymphatisches targeting
GB0525864D0 (en) * 2005-12-20 2006-02-01 Novartis Ag Organic compounds
WO2008011615A2 (en) 2006-07-20 2008-01-24 Orbusneich Medical, Inc. Bioabsorbable polymeric composition for a medical device
CN101631513B (zh) 2006-10-20 2013-06-05 奥巴斯尼茨医学公司 可生物吸收的聚合物组合物和医疗设备
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
CN101390828B (zh) * 2007-02-12 2010-06-09 济南康泉医药科技有限公司 同载抗代谢类药物和增效剂的抗癌组合物
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CA2763365C (en) 2009-05-29 2016-09-13 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
ES2362525B8 (es) 2009-10-08 2013-01-03 Azurebio, S.L. Formulación de medicamentos en forma de agujas percutaneas penetrantes.
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
NZ717490A (en) 2010-03-29 2017-12-22 Abraxis Bioscience Llc Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
JP5824511B2 (ja) 2010-05-03 2015-11-25 テイコク ファーマ ユーエスエー インコーポレーテッド 非水タキサンプロエマルジョン配合物ならびにそれを調製および使用する方法
KR20190130050A (ko) 2010-06-04 2019-11-20 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
KR101839864B1 (ko) * 2012-09-21 2018-03-20 인텐시티 쎄라퓨틱스, 인코포레이티드 암을 치료하는 방법
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9545447B2 (en) * 2013-01-04 2017-01-17 The Texas A&M University System Polymer-drug systems
AU2016270558B2 (en) 2015-06-04 2020-08-13 Crititech, Inc. Nozzle assembly and methods for use
KR102317108B1 (ko) 2016-04-04 2021-10-25 크리티테크, 인크. 고형 종양의 치료 방법
KR20200014279A (ko) 2017-06-09 2020-02-10 크리티테크, 인크. 항신생물 입자의 낭내 주사에 의한 상피낭종의 치료
CN110799176A (zh) 2017-06-14 2020-02-14 克里蒂泰克公司 治疗肺部疾病的方法
KR20200064112A (ko) 2017-10-03 2020-06-05 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
WO2020072090A1 (en) * 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
BR112021005104A2 (pt) 2018-10-16 2021-06-08 US Nano Food & Drug INC formulação de injeção intratumoral
EP4135686A1 (de) 2020-04-13 2023-02-22 US Nano Food & Drug Inc Basische chemotherapeutische intratumor-injektionsformulierung
GB2623319A (en) 2022-10-11 2024-04-17 Af Chempharm Ltd Method of synthesis of chloro-oxo-dioxaphospholane oxides and derivates

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3271329A (en) 1958-09-19 1966-09-06 Eastman Kodak Co Method for producing polymers derived from phosphites and glycols
US3442982A (en) 1965-10-15 1969-05-06 Weston Chemical Corp Polyphosphites of 2,2-dimethyl-3-hydroxypropyl - 2 - dimethyl - 3-hydroxypropionate
FR2219193B1 (de) 1973-02-28 1976-05-21 Rhone Poulenc Sa
US3932566A (en) 1974-09-16 1976-01-13 Celanese Corporation Phosphonate polymers
US4100354A (en) 1976-08-05 1978-07-11 Owens-Corning Fiberglass Corporation Terephthalate ester polyols
US4259222A (en) 1978-08-16 1981-03-31 Basf Wyandotte Corporation Linear saturated polyesters of phosphoric acid and halogenated diols as flame-retardant additives and coatings
DE2925206A1 (de) 1979-06-22 1981-01-29 Bayer Ag Aromatische polyesterphosphonate, verfahren zu ihrer herstellung und ihre verwendung zur herstellung thermoplastischer formkoerper
FR2498612A1 (fr) 1981-01-26 1982-07-30 Peters Ligatures Nouveaux polymeres insolubles a biodegradabilite reglable a volonte, leurs procedes de preparation et leur application en tant que biomateriaux
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4474937A (en) 1983-10-03 1984-10-02 The Dow Chemical Company Phosphorus-modified polyestercarbonate resins
US4481353A (en) 1983-10-07 1984-11-06 The Children's Medical Center Corporation Bioresorbable polyesters and polyester composites
US4746462A (en) 1985-02-21 1988-05-24 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Phosphoric ester compound
US4789724A (en) 1986-10-17 1988-12-06 Massachusetts Institute Of Technology Preparation of anhydride copolymers
US4978332A (en) 1987-09-28 1990-12-18 Matrix Pharmaceutical, Inc. Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5194581A (en) 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5256765A (en) 1989-03-09 1993-10-26 The Johns Hopkins University School Of Medicine Biodegradable poly(phosphate esters)
US5162115A (en) 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
WO1994023699A1 (en) 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Long-acting treatment by slow-release delivery of antisense oligodeoxyribonucleotides from biodegradable microparticles
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
JPH09507233A (ja) 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
DE4404365A1 (de) 1994-02-11 1995-08-17 Cassella Ag Phosphin- und phosphonsäuregruppenhaltige Polykondensate
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5637085A (en) 1995-11-20 1997-06-10 Cardinale; Robert M. Method of cancer tumor treatment by slow release delivery of 1,2,4-benzotriazine oxides to tumor site
EP1479707A3 (de) 1996-04-23 2005-05-18 Ipsen Manufacturing Ireland Limited Bioabbaubare Polyester und Verfahren zu ihrer Herstellung
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
AU744095B2 (en) 1997-03-27 2002-02-14 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of ovarian cancer
UA54505C2 (uk) 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання
NZ500649A (en) * 1997-04-03 2001-05-25 Guilford Pharm Inc Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making a biosorbable suture, an orthopedic appliance or bone cement for repairing injuries to bone or connective tissue
US5912225A (en) 1997-04-14 1999-06-15 Johns Hopkins Univ. School Of Medicine Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same
US6403675B1 (en) * 1997-04-30 2002-06-11 Guilford Pharmaceuticals, Inc. Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same
ATE216712T1 (de) 1997-06-18 2002-05-15 Guilford Pharm Inc Zweistufige lösungspolymerisation von hochmolekularen poly(phosphorestern)
US6028163A (en) 1997-06-27 2000-02-22 Guilford Pharmaceuticals Inc. Solution polymerization of high molecular weight poly(phosphoesters) in toluene
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
EP1117441A2 (de) 1998-10-02 2001-07-25 Guilford Pharmaceuticals Inc. Bioabbaubare terephthalat polyester-polyphosphonat und polyester-polyphosphit polymere,zusammensetzungen,gegenstände und verfahren für ihre verwendung
US6419709B1 (en) * 1998-10-02 2002-07-16 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same
US6350464B1 (en) * 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
WO2000064437A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
US20020041897A1 (en) 2000-07-07 2002-04-11 Wenbin Dang Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
WO2002005800A2 (en) * 2000-07-17 2002-01-24 Guilford Pharmaceuticals, Inc. Compositions for sustained release of analgesic agents, and methods of making and using the same
US20020198135A1 (en) * 2000-10-12 2002-12-26 Wenbin Dang Compositions for release of radiosensitizers, and methods of making and using the same
US20030134892A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of head and neck cancers, and methods of making and using the same
US20030133903A1 (en) * 2001-07-19 2003-07-17 Wenbin Dang Compositions for treatment of prostate cancers and methods of making and using the same

Also Published As

Publication number Publication date
IL145492A0 (en) 2002-06-30
US7101568B2 (en) 2006-09-05
AU3762500A (en) 2000-10-16
HUP0201436A3 (en) 2003-04-28
WO2000057852A3 (en) 2001-02-15
JP2002540137A (ja) 2002-11-26
PL351280A1 (en) 2003-04-07
TR200102801T2 (tr) 2002-04-22
CZ20013260A3 (cs) 2002-01-16
CA2368621A1 (en) 2000-10-05
NO20014662D0 (no) 2001-09-25
EP1185249A2 (de) 2002-03-13
US6537585B1 (en) 2003-03-25
WO2000057852A2 (en) 2000-10-05
CN1367684A (zh) 2002-09-04
NO20014662L (no) 2001-11-20
ATE306251T1 (de) 2005-10-15
HUP0201436A2 (en) 2002-09-28
JP2011219483A (ja) 2011-11-04
CA2368621C (en) 2010-05-25
KR20010111578A (ko) 2001-12-19
EP1185249B1 (de) 2005-10-12
US20030203033A1 (en) 2003-10-30
AU778279B2 (en) 2004-11-25
BR0009213A (pt) 2002-04-16
DE60023138T2 (de) 2006-08-17

Similar Documents

Publication Publication Date Title
ATE306251T1 (de) Verwendung eines biologisch abbaubaren polymers
PT1061900E (pt) Composicoes e metodos para libertacao de uma droga
PT959873E (pt) Composicao de gel e metodos
DE60131991D1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
NO20013402D0 (no) Fremgangsmåter for behandling av ovarialcancer, poly(fosfoester)preparater, og bionedbrytbare gjenstander for detsamme
MY129356A (en) Electrospun pharmaceutical compositions
BR0012588A (pt) Copolìmero em bloco, composição para suprimento de agente bioativo, e, formulação de medicamento para implantação subcutânea ou injeção intravenosa
RS50397B (sr) Farmaceutska smeša
BR0317787A (pt) Fibra aglutinante bicomponente
BR0016828A (pt) Polìmeros superabsorventes
DE60023107D1 (de) Zubereitungen mit verbesserter kontrollierter freisetzung
SE9802208D0 (sv) Novel compounds
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
ES2178631T3 (es) Composicion a base de un oligomero y un polimero, inyectable y biodegradable.
ATE264674T1 (de) Verwendung von hyaluronsäure zur behandlung der bestrahlungs-blasenentzündung
TR200103151T2 (tr) Karboksipeptidaz U inhibitörü ile trombin inhibitörünü içeren farmasötik bir formülasyon.
WO2002006280A3 (en) INHIBITORS OF FACTOR Xa
EP1150621A4 (de) Methode und zusammensetzung von fluorinierten polymeren zur verhütung von chirurgischen verklebungen
TR200101346T2 (tr) Rilüzol ve alfa-tokoferol bileşimi
SE9904483D0 (sv) New use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MGI GP, INC. (N.D.GES.D. STAATES DELAWARE), BA, US

8327 Change in the person/name/address of the patent owner

Owner name: EISAI CORPORATION OF NORTH AMERICA, WOODCLIFF , US

8327 Change in the person/name/address of the patent owner

Owner name: EISAI INC., WOODCLIFF LAKE, N.J., US